Cardiovascular Complications in Coronavirus Disease 2019—Pathogenesis and Management

Marcos I. Restrepo; Judith Marin-Corral; Juan J. Rodriguez; Valeria Restrepo; Rodrigo Cavallazzi

doi:10.1055/s-0042-1760096

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2023; 44(01): 021-034
DOI: 10.1055/s-0042-1760096

Review Article

Cardiovascular Complications in Coronavirus Disease 2019—Pathogenesis and Management

Authors

Marcos I. Restrepo

¹Division of Pulmonary Diseases and Critical Care Medicine, University of Texas Health San Antonio, San Antonio, Texas

²Section of Pulmonary and Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, Texas
Judith Marin-Corral

¹Division of Pulmonary Diseases and Critical Care Medicine, University of Texas Health San Antonio, San Antonio, Texas

³Critical Care Department, Hospital del Mar-IMIM; Critical Illness Research Group (GREPAC), Barcelona, Spain

⁴Department of Critical Care, Critical Illness Research Group (GREPAC), Barcelona, Spain
Juan J. Rodriguez

⁵Department of Medicine, Universidad Autónoma de Bucaramanga, Colombia
Valeria Restrepo

⁶Department of Biology, University of Texas San Antonio - UTSA, San Antonio, Texas
Rodrigo Cavallazzi

⁷Division of Pulmonary, Critical Care Medicine, and Sleep Disorders, University of Louisville, Louisville, Kentucky

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has caused a devastating impact on morbidity and mortality around the world. Severe acute respiratory syndrome-coronavirus-2 has a characteristic tropism for the cardiovascular system by entering the host cells and binding to angiotensin-converting enzyme 2 receptors, which are expressed in different cells, particularly endothelial cells. This endothelial injury is linked by a direct intracellular viral invasion leading to inflammation, microthrombosis, and angiogenesis. COVID-19 has been associated with acute myocarditis, cardiac arrhythmias, new onset or worsening heart failure, ischemic heart disease, stroke, and thromboembolic disease. This review summarizes key relevant literature regarding the epidemiology, diagnosis, treatment, and preventive measures related to cardiovascular complications in the setting of COVID-19.

Keywords

COVID-19 - cardiovascular events - complications

Volltext

Referenzen

References
1 Centers for Disease Control and Prevention. Scientific brief: SARS-CoV-2 transmission. Accessed May 16, 2022 at: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html#anchor_1619805150492
2 Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 2020; 26 (07) 1470-1477
3 Centers for Disease Control and Prevention. COVID-19 mortality overview. Accessed May 16, 2022 at: https://www.cdc.gov/nchs/COVID19/mortality-overview.htm
4 World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://COVID19.who.int/ Published 2022, May 31. Accessed
5 World Health Organization. Global excess deaths associated with COVID-19. Published 2022, May. Accessed May 16, 2022 at: https://www.who.int/data/stories/global-excess-deaths-associated-with-COVID-19-january-2020-december-2021
6 Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203 (02) 631-637
7 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020; 383 (02) 120-128
8 Shi S, Qin M, Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5 (07) 802-810
9 Lu JQ, Lu JY, Wang W. et al. Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19. EBioMedicine 2022; 76: 103821
10 Xu Q, Samanapally H, Nathala P. et al; Center of Excellence for Research in Infectious Diseases (CERID) Coronavirus Study Group on behalf of the COVID-19 CardioVascular Research Group (COVID-CVRG). Outcomes and risk factors for cardiovascular events in hospitalized COVID-19 patients. J Cardiothorac Vasc Anesth 2021; 35 (12) 3581-3593
11 Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28 (03) 583-590
12 Saad M, Kennedy KF, Imran H. et al. Association between COVID-19 diagnosis and in-hospital mortality in patients hospitalized with ST-segment elevation myocardial infarction. JAMA 2021; 326 (19) 1940-1952
13 Vahey GM, Marshall KE, McDonald E. et al; Colorado Investigation Team2. Symptom profiles and progression in hospitalized and nonhospitalized patients with coronavirus disease, Colorado, USA, 2020. Emerg Infect Dis 2021; 27 (02) 385-395
14 Bordon J, Akca O, Furmanek S. et al. Acute Respiratory Distress Syndrome and Time to Weaning Off the Invasive Mechanical Ventilator among Patients with COVID-19 Pneumonia. J Clin Med 2021; 10 (13) 2935
15 Logothetis CN, Weppelmann TA, Jordan A. et al. D-dimer testing for the exclusion of pulmonary embolism among hospitalized patients with COVID-19. JAMA Netw Open 2021; 4 (10) e2128802-e2128802
16 Zhao B-C, Liu W-F, Lei S-H. et al. Prevalence and prognostic value of elevated troponins in patients hospitalised for coronavirus disease 2019: a systematic review and meta-analysis. J Intensive Care 2020; 8 (01) 88
17 Mahmud E, Dauerman HL, Welt FGP. et al. Management of acute myocardial infarction during the COVID-19 pandemic: a position statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). J Am Coll Cardiol 2020; 76 (11) 1375-1384
18 Bertini M, Ferrari R, Guardigli G. et al. Electrocardiographic features of 431 consecutive, critically ill COVID-19 patients: an insight into the mechanisms of cardiac involvement. Europace 2020; 22 (12) 1848-1854
19 French G, Hulse M, Nguyen D. et al. Impact of hospital strain on excess deaths during the COVID-19 pandemic - United States, July 2020-July 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (46) 1613-1616
20 Fried JA, Ramasubbu K, Bhatt R. et al. The variety of cardiovascular presentations of COVID-19. Circulation 2020; 141 (23) 1930-1936
21 Katsanos AH, Palaiodimou L, Zand R. et al. The impact of SARS-CoV-2 on stroke epidemiology and care: a meta-analysis. Ann Neurol 2021; 89 (02) 380-388
22 Metkus TS, Sokoll LJ, Barth AS. et al. Myocardial injury in severe COVID-19 compared with non-COVID-19 acute respiratory distress syndrome. Circulation 2021; 143 (06) 553-565
23 Malik P, Patel U, Mehta D. et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med 2021; 26 (03) 107-108
24 Ni W, Yang X, Liu J. et al. Acute Myocardial Injury at Hospital Admission Is Associated With All-Cause Mortality in COVID-19. J Am Coll Cardiol 2020; 76 (01) 124-125
25 Cipriani A, Capone F, Donato F. et al. Cardiac injury and mortality in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis. Intern Emerg Med 2021; 16 (02) 419-427
26 Lombardi CM, Carubelli V, Iorio A. et al. Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: results of a multicenter study. JAMA Cardiol 2020; 5 (11) 1274-1280
27 Chung MK, Zidar DA, Bristow MR. et al. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res 2021; 128 (08) 1214-1236
28 Zhan L, Liu Y, Cheng Y, Guo W, Yang J. Predictive value of neutrophil/lymphocyte ratio (NLR) on cardiovascular events in patients with COVID-19. Int J Gen Med 2021; 14: 3899-3907
29 Yu JS, Chen RD, Zeng LC, Yang HK, Li H. Myoglobin offers higher accuracy than other cardiac-specific biomarkers for the prognosis of COVID-19. Front Cardiovasc Med 2021; 8: 686328
30 García de Guadiana-Romualdo L, Martínez Martínez M, Rodríguez Mulero MD. et al. Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. Int J Infect Dis 2021; 111: 211-218
31 Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis 2020; 314: 58-62
32 Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17 (05) 259-260
33 Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The Architecture of SARS-CoV-2 Transcriptome. Cell 2020; 181 (04) 914-921 .e10
34 Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10 (02) 102-108
35 Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A 2009; 106 (14) 5871-5876
36 Ziegler CGK, Allon SJ, Nyquist SK. et al; HCA Lung Biological Network. Electronic address: lung-network@humancellatlas.org, ; HCA Lung Biological Network. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020; 181 (05) 1016-1035 .e19
37 Bräuninger H, Stoffers B, Fitzek ADE. et al. Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart. Cardiovasc Res 2022; 118 (02) 542-555
38 Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009; 7 (06) 439-450
39 Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 2020; 17 (09) 543-558
40 Guo L, Ren L, Yang S. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020; 71 (15) 778-785
41 Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog 2020; 16 (07) e1008737
42 Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20 (06) 363-374
43 Hasanvand A. COVID-19 and the role of cytokines in this disease. Inflammopharmacology 2022; 30 (03) 789-798
44 Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res 2020; 69 (12) 1181-1189
45 Mahenthiran AK, Mahenthiran AK, Mahenthiran J. Cardiovascular system and COVID-19: manifestations and therapeutics. Rev Cardiovasc Med 2020; 21 (03) 399-409
46 Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect 2020; 9 (01) 558-570
47 Chu H, Chan JF, Wang Y. et al. Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. Clin Infect Dis 2020; 71 (06) 1400-1409
48 Gu ZC, Zhang C, Kong LC. et al. Incidence of myocardial injury in coronavirus disease 2019 (COVID-19): a pooled analysis of 7,679 patients from 53 studies. Cardiovasc Diagn Ther 2020; 10 (04) 667-677
49 Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 2021; 398 (10300): 599-607
50 Chew NWS, Ow ZGW, Teo VXY. et al. The Global Effect of the COVID-19 Pandemic on STEMI Care: A Systematic Review and Meta-analysis. Can J Cardiol 2021; 37 (09) 1450-1459
51 Helal A, Shahin L, Abdelsalam M, Ibrahim M. Global effect of COVID-19 pandemic on the rate of acute coronary syndrome admissions: a comprehensive review of published literature. Open Heart 2021; 8 (01) e001645
52 Sofi F, Dinu M, Reboldi G. et al. Worldwide differences of hospitalization for ST-segment elevation myocardial infarction during COVID-19: A systematic review and meta-analysis. Int J Cardiol 2022; 347: 89-96
53 Zhu Y, Xing W, Wang H, Song J, Sun Z, Li X. Characteristics of patients with ST-segment elevated myocardial infarction (STEMI) at the initial stage of the COVID-19 pandemic: a systematic review and meta-analysis. Infect Dis (Lond) 2021; 53 (11) 865-875
54 Diaz-Arocutipa C, Torres-Valencia J, Saucedo-Chinchay J, Cuevas C. ST-segment elevation in patients with COVID-19: a systematic review. J Thromb Thrombolysis 2021; 52 (03) 738-745
55 Gharibzadeh A, Shahsanaei F, Rahimi Petrudi N. Clinical and cardiovascular characteristics of patients suffering st-segment elevation myocardial infarction after COVID-19: a systematic review and meta-analysis. Curr Probl Cardiol 2023; 48 (01) 101045
56 Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J 2021; 42 (02) 206 [Erratum in: Eur Heart J. 2021 Jan 7;42(2):191. PMID: 32176300; PMCID: PMC7184348]
57 Inciardi RM, Lupi L, Zaccone G. et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5 (07) 819-824
58 Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Lane DA, Lip GYH. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur J Clin Invest 2021; 51 (11) e13679
59 Ojha V, Verma M, Pandey NN. et al. Cardiac magnetic resonance imaging in coronavirus disease 2019 (COVID-19): a systematic review of cardiac magnetic resonance imaging findings in 199 patients. J Thorac Imaging 2021; 36 (02) 73-83
60 Kim JY, Han K, Suh YJ. Prevalence of abnormal cardiovascular magnetic resonance findings in recovered patients from COVID-19: a systematic review and meta-analysis. J Cardiovasc Magn Reson 2021; 23 (01) 100
61 Furqan MM, Verma BR, Cremer PC, Imazio M, Klein AL. Pericardial diseases in COVID19: a contemporary review. Curr Cardiol Rep 2021; 23 (07) 90
62 Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus disease 2019 (COVID-19) CT findings: a systematic review and meta-analysis. J Am Coll Radiol 2020; 17 (06) 701-709
63 Varney JA, Dong VS, Tsao T. et al. COVID-19 and arrhythmia: an overview. J Cardiol 2022; 79 (04) 468-475
64 Nagamine T, Randhawa S, Nishimura Y. et al. Characteristics of bradyarrhythmia in patients with COVID-19: Systematic scoping review. Pacing Clin Electrophysiol 2022; 45 (04) 556-566
65 Szarpak L, Filipiak KJ, Skwarek A. et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: A systematic review and meta-analysis. Cardiol J 2022; 29 (01) 33-43
66 Tan Z, Huang S, Mei K. et al. The Prevalence and Associated Death of Ventricular Arrhythmia and Sudden Cardiac Death in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2022; 8: 795750
67 Mir T, Sattar Y, Ahmad J. et al. Outcomes of in-hospital cardiac arrest in COVID-19 patients: A proportional prevalence meta-analysis. Catheter Cardiovasc Interv 2022; 99 (01) 1-8
68 Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev 2013; 2013 (10) CD004471
69 Caiazzo E, Rezig AOM, Bruzzese D. et al. Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials. Pharmacol Res 2022; 176: 106053
70 Sarfraz A, Sarfraz Z, Razzack AA, Patel G, Sarfraz M. Venous Thromboembolism, Corticosteroids and COVID-19: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost 2021; 27: 10 76029621993573
71 Selvaraj V, Finn A, Lal A, Khan MS, Dapaah-Afriyie K, Carino GP. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine 2022; 49: 101489
72 RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397 (10274): 605-612
73 Diaz-Arocutipa C, Brañez-Condorena A, Hernandez AV. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2021; 30 (06) 694-706
74 Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Infect Dis 2022; 74 (06) 1022-1029
75 Axfors C, Janiaud P, Schmitt AM. et al. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis 2021; 21 (01) 1170
76 Osborne TF, Veigulis ZP, Arreola DM, Mahajan SM, Röösli E, Curtin CM. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS One 2021; 16 (02) e0246825
77 Martha JW, Pranata R, Lim MA, Wibowo A, Akbar MR. Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates. Int J Infect Dis 2021; 108: 6-12
78 Al Harthi AF, Aljuhani O, Korayem GB. et al. Evaluation of low-dose aspirin use among critically ill patients with COVID-19: a multicenter propensity score matched study. J Intensive Care Med 2022; 37 (09) 1238-1249
79 Bradbury CA, Lawler PR, Stanworth SJ. et al; REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 2022; 327 (13) 1247-1259
80 Ramacciotti E, Barile Agati L, Calderaro D. et al; MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 399 (10319): 50-59
81 World Health Organization. COVID-19 advice for the public: Getting vaccinated. Accessed 25 May 2022 at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/COVID-19-vaccines/advice
82 World Health Organization. COVID-19 vaccines advice. Accessed 25 May 2022 at: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(COVID-19)-vaccines
83 Mayo Clinic. Different types of COVID-19 vaccines: How they work. Accessed 25 May 2022 at: https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/different-types-of-COVID-19-vaccines/art-20506465
84 CDC. The Vaccine Adverse Event Reporting System (VAERS). CDC WONDER On-line Database; 2021
85 Jeet Kaur R, Dutta S, Charan J. et al. Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database. Int J Gen Med 2021; 14: 3909-3927
86 AstraZeneca. COVID-19 vaccine AstraZeneca analysis print. Accessed December 6, 2022 at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach-ment_data/file/972833/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf
87 Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155 (05) 469-473
88 Peretto G, Sala S, Rizzo S. et al. Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation. J Am Coll Cardiol 2020; 75 (09) 1046-1057
89 Marco García MT, Torres Lana Á, Anta Agudo MB, Rufino Delgado MT. Tachycardia as an undescribed adverse effect to the Comirnaty vaccine (BNT162b2 Pfizer-BioNTech Covid-19 vaccine): description of 3 cases with a history of SARS-CoV-2 disease [in Spanish]. Enferm Infecc Microbiol Clin (Engl Ed) 2021; 40 (05) 276-277
90 Briefing Document FDA. Pfizer-BioNTech COVID-19 Vaccine. Vaccines and related biological products advisory committee meeting; [updated March 8, 2021]. Accessed July16, 2021. Accessed March 18, 2021 Available from: https://www.fda.gov/media/144245/download
91 Edler C, Klein A, Schröder AS, Sperhake JP, Ondruschka B. Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty). Leg Med (Tokyo) 2021; 51: 101895
92 Briefing Document FDA. Moderna COVID-19 Vaccine. Vaccines and related biologi- cal products advisory committee meeting. Accessed December 6, 2022 at: https://www.fda.gov/media/144434/download
93 Kounis NG, Mazarakis A, Tsigkas G, Giannopoulos S, Goudevenos J. Kounis syndrome: a new twist on an old disease. Future Cardiol 2011; 7 (06) 805-824
94 Özdemir IH, Özlek B, Özen MB, Gündüz R, Bayturan Ö. Type 1 Kounis syndrome induced by inactivated SARS-COV-2 vaccine. J Emerg Med 2021; 61 (04) e71-e76
95 Boivin Z, Martin J. Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect. Cureus 2021; 13 (03) e13651
96 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytope- nia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021; 384 (22) 2092-2101
97 Li X, Ostropolets A, Makadia R. et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. 2021.
98 Barda N, Dagan N, Ben-Shlomo Y. et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 2021; 385 (12) 1078-1090
99 Chatterjee S, Ojha UK, Vardhan B, Tiwari A. Myocardial infarction after COVID-19 vaccination-casual or causal?. Diabetes Metab Syndr 2021; 15 (03) 1055-1056
100 Fazlollahi A, Zahmatyar M, Noori M. et al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev Med Virol 2022; 32 (04) e2318
101 Sadoff J, Davis K, Douoguih M. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination - response from the manufacturer. N Engl J Med 2021; 384 (20) 1965-1966
102 U.S. Food and Drug Administration. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. Accessed December 6, 2022 at: https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-COVID-19-vaccine
103 Shay DK, Gee J, Su JR. et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (18) 680-684
104 Marcucci R, Marietta M. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. Intern Emerg Med 2021; 16 (05) 1113-1119
105 Hafeez MU, Ikram M, Shafiq Z. et al. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): a systematic review and post hoc analysis. Clin Appl Thromb Hemost 2021; 27: 10 760296211048815
106 Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020; 76: 14-20
107 Liu M, Gu C, Wu J, Zhu Y. Amino acids 1 to 422 of the spike protein of SARS associated coronavirus are required for induction of cyclooxygenase-2. Virus Genes 2006; 33 (03) 309-317
108 WHO. Guidance for clinical case management of thrombosis with thrombo- cytopenia syndrome(TTS) following vaccination to prevent coronavirus dis- ease (COVID-19). Accessed December 6, 2022 at: https://www.who.int/publications/i/item/WHO-2019-nCoV-TTS-2021.1
109 Patriquin CJ, Laroche V, Selby R. et al. Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 385 (09) 857-859
110 Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. [published correction appears in N Engl J Med. 2021 Jun 10;384(23):e92] N Engl J Med 2021; 384 (23) 2254-2256
111 Salah HM, Mehta JL. COVID-19 vaccine and myocarditis. Am J Cardiol 2021; 157: 146-148
112 Kim HW, Jenista ER, Wendell DC. et al. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol 2021; 6 (10) 1196-1201
113 Gargano JW, Wallace M, Hadler SC. et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (27) 977-982